-
PerkinElmer Beats Estimates - Analyst Blog
Friday, November 5, 2010 - 12:32pm | 363PerkinElmer (PKI) reported third-quarter 2010 adjusted (excluding one-time expenses) earnings per share of 31 cents, beating the Zacks Consensus Estimate of 29 cents and the year-ago earnings of 27 cents per share. The quarterly results surpassed the company's previously issued guidance in the...
-
Narrower Q3 Loss at CTIC - Analyst Blog
Friday, November 5, 2010 - 12:32pm | 545Cell Therapeutics Inc. (CTIC) suffered a net loss of $15.6 million (2 cents per share) in the third quarter of 2010 as opposed to the net loss of $48.8 million (9 cents per share) suffered in the year-ago quarter. The narrower loss was primarily attributable to lower operating expenses, lower...
-
Hapoalim Securities Raises Target On Nektar Therapeutics (NKTR)
Friday, November 5, 2010 - 9:43am | 144Hapoalim Securities raised its price target on Nektar Therapeutics (NASDAQ: NKTR) to $19 from $16. It is reiterating its Buy rating on shares. In a note to clients, Hapoalim writes, "After the impressive Phase II ovarian and breast cancer data, Nektar stated that it expects to partner NKTR-102 by...
-
Zacks #1 Rank Additions for Friday - Tale of the Tape
Friday, November 5, 2010 - 9:33am | 299Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List today: Akorn Inc (AKRX) Atlas Air Worldwide Holdings Inc (AAWW) Bio-Rad Laboratories Inc (BIO) Black Box Corp (BBOX) C&F Financial Corp (CFFI) View the entire Zacks #1 Rank List. ATLAS AIR WORLD (AAWW): Free Stock Analysis...
-
Jefferies & Company Raises Dionex Corporation FY11 EPS To $3.70
Friday, November 5, 2010 - 9:23am | 93Dionex Corporation's (NASDAQ: DNEX) core focus in liquid chromatography analytical technologies, success in penetrating adjacent market niches, effective cost structure management, and disciplined capital re-deployment history have contributed to above-average organic revenue growth and...
-
Luminex Reports Mixed 3Q
Friday, November 5, 2010 - 8:08am | 182Piper Jaffray has published a research report on Luminex Corporation (NASDAQ: LMNX) after the company reported revenues and losses per share lower than expected across the board. In the report, Piper Jaffray writes "Luminex increased revenue by 16.3% yoy to $33.9M, below our $34.8M and Street...
-
pSivida Corp. Reports First Quarter EPS of $(0.17)
Friday, November 5, 2010 - 7:35am | 182pSivida Corp. (NASDAQ: PSDV) today announced its first quarter results. Revenues for the 2010 quarter were $476,000 as compared to $3.4 million a year earlier. The change from the prior year reflects the previously announced completion of the amortization of deferred revenue from the Company's...
-
Exelixis Shares Fall 5.6% On Earnings And Revenue Miss (EXEL)
Thursday, November 4, 2010 - 7:27pm | 250Exelixis, Inc. (Nasdaq: EXEL) released financial results on Thursday after the market closed that missed Wall Street estimates and sent the company's share price falling. Exelixis, Inc reported a 3rd quarter net loss of 8 cents per share, on revenue of $54.5 million. According to a poll of analysts...
-
Luminex Corporation Reports Third Quarter EPS of $(0.02)
Thursday, November 4, 2010 - 4:35pm | 196Luminex Corporation (Nasdaq: LMNX) today announced financial results for the third quarter and nine months ended September 30, 2010. Financial and operating highlights include the following: Consolidated revenue for the third quarter of 2010 was $33.9 million, a 16 percent increase over...
-
Sequenom Reports Third Quarter and First Nine Months 2010 Financial Results: Loss Per Share of $0.30
Thursday, November 4, 2010 - 4:24pm | 150Sequenom, Inc. (Nasdaq: SQNM) today reported its financial results for the third quarter and nine-months ended September 30, 2010. Third Quarter Results * Total revenue for the third quarter of 2010 grew 27% to $11.7 million, compared with $9.2 million for the third quarter of 2009. The...
-
AMAG Narrows Loss, Cuts Jobs - Analyst Blog
Thursday, November 4, 2010 - 3:03pm | 546AMAG Pharmaceuticals, Inc. (AMAG) posted a loss of 81 cents per share during the third quarter of fiscal 2010, lower than the Zacks Consensus Estimate of a loss of $1.09 and the year-ago loss of $1.29. Increased Feraheme sales helped narrow the loss incurred by the company. Revenues Third...
-
Covance Meets EPS Estimates - Analyst Blog
Thursday, November 4, 2010 - 1:54pm | 509Covance (CVD) reported net loss per share of 49 cents during the third quarter of fiscal 2010 compared with an EPS of 79 cents in the year-ago period. However, after adjusting for certain items, the company reported an EPS of 50 cents, meeting the Zacks Consensus Estimate and surpassing the year-...
-
Response Genetics, Inc. Reports Third Quarter EPS of $(0.06)
Thursday, November 4, 2010 - 8:27am | 125Response Genetics Inc. (Nasdaq: RGDX) today announced its consolidated financial results for the three and nine months ended September 30, 2010. Total revenue increased by 147 percent to $5.6 million for the third quarter ended September 30, 2010, compared to $2.3 million for the same period last...
-
J.P. Morgan Overweight On Covance (CVD)
Thursday, November 4, 2010 - 7:30am | 120J.P. Morgan Chase & Co. has an Overweight rating on Covance (NYSE: CVD) after it reported Q3 earnings. It has a $48 price target on shares. In a note to clients, J.P. Morgan writes, "Covance reported 3Q10 results that were roughly in line with our expectations, though 4Q10 EPS guidance of...
-
Covance Reports Significant Cost Initiatives
Thursday, November 4, 2010 - 7:29am | 210Goldman Sachs has published a research report on Covance, Inc. (NYSE: CVD) after the company reported 3Q EPS directly in-line with Goldman Sachs and Consensus. In the report, Goldman Sachs writes "CVD reported adjusted 3Q EPS of $0.50 (which excluded ~$0.01-$0.02 from 2Q cost actions), versus GS/...